Inhee Mook-Jung

List of Publications by Year
in descending order

160 papers	8,903 citations	26630 56 h-index	51608 86 g-index
165 all docs	165 docs citations	165 times ranked	14436 citing authors

#	Article	IF	Citations
1	Application of QPLEXTM biomarkers in cognitively normal individuals across a broad age range and diverse regions with cerebral amyloid deposition. Experimental and Molecular Medicine, 2022, 54, 61-71.	7.7	2
2	White matter-associated microglia: New players in brain aging and neurodegenerative diseases. Ageing Research Reviews, 2022, 75, 101574.	10.9	20
3	Conformation-specific Antibodies Targeting Aggregated Forms of Î±-synuclein Block the Propagation of Synucleinopathy. Experimental Neurobiology, 2022, 31, 29-41.	1.6	4
4	Gut Microbiota as a Hidden Player in the Pathogenesis of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, 86, 1501-1526.	2.6	9
5	Amyloidâ€Î² activates NLRP3 inflammasomes by affecting microglial immunometabolism through the Sykâ€AMPK pathway. Aging Cell, 2022, 21, e13623.	6.7	25
6	Neurotoxicity of phenylalanine on human iPSC-derived cerebral organoids. Molecular Genetics and Metabolism, 2022, 136, 132-144.	1.1	7
7	Gut Microbiota as a Hidden Player in the Pathogenesis of Alzheimerâ€™s Disease. Advances in Alzheimer's Disease, 2022, , .	0.2	0
8	A logical network-based drug-screening platform for Alzheimerâ€™s disease representing pathological features of human brain organoids. Nature Communications, 2021, 12, 280.	12.8	88
9	miR-351-5p/Miro2 axis contributes to hippocampal neural progenitor cell death via unbalanced mitochondrial fission. Molecular Therapy - Nucleic Acids, 2021, 23, 643-656.	5.1	13
10	The clinical use of blood-test factors for Alzheimerâ€™s disease: improving the prediction of cerebral amyloid deposition by the QPLEXTM Alz plus assay kit. Experimental and Molecular Medicine, 2021, 53, 1046-1054.	7.7	5
11	Plexin-A4 mediates amyloid-Î²â€“induced tau pathology in Alzheimerâ€™s disease animal model. Progress in Neurobiology, 2021, 203, 102075.	5.7	5
12	Performance of the QPLEXâ„¢ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition. Alzheimer's Research and Therapy, 2021, 13, 12.	6.2	6
13	A networkâ€based drugâ€screening platform for Alzheimerâ€™s disease by integrating mathematical modeling and pathological features of human brain organoids. Alzheimer's and Dementia, 2021, 17, .	0.8	0
14	Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimerâ€™s disease animal model. Gut, 2020, 69, 283-294.	12.1	336
15	Acetylation changes tau interactome to degrade tau in Alzheimerâ€™s disease animal and organoid models. Aging Cell, 2020, 19, e13081.	6.7	77
16	Amyloid beta regulates ER exit sites formation through Oâ€GlcNAcylation triggered by disrupted calcium homeostasis. Biology of the Cell, 2020, 112, 439-451.	2.0	9
17	New Microglia on the Block. Cell Metabolism, 2020, 31, 664-666.	16.2	6
18	Peripheral inflammatory biomarkers in Alzheimerâ€™s disease: a brief review. BMB Reports, 2020, 53, 10-19.	2.4	119

#	Article	IF	Citations
19	Brain somatic mutations observed in Alzheimerâ€™s disease associated with aging and dysregulation of tau phosphorylation. Nature Communications, 2019, 10, 3090.	12.8	103
20	A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease. Cell Metabolism, 2019, 30, 493-507.e6.	16.2	374
21	Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons. Journal of Alzheimer's Disease, 2019, 70, 667-680.	2.6	36
22	Hearing loss as a risk factor for cognitive impairment and loss of synapses in the hippocampus. Behavioural Brain Research, 2019, 372, 112069.	2.2	17
23	Mimicry of Central-Peripheral Immunity in Alzheimer's Disease and Discovery of Neurodegenerative Roles in Neutrophil. Frontiers in Immunology, 2019, 10, 2231.	4.8	20
24	Prognostic plasma protein panel for AÎ² deposition in the brain in Alzheimerâ€™s disease. Progress in Neurobiology, 2019, 183, 101690.	5.7	20
25	Plasma tau/amyloid-Î²1â€“42 ratio predicts brain tau deposition and neurodegeneration in Alzheimerâ€™s disease. Brain, 2019, 142, 771-786.	7.6	117
26	Harnessing Intramolecular Rotation To Enhance Twoâ€photon Imaging of AÎ² Plaques through Minimizing Background Fluorescence. Angewandte Chemie - International Edition, 2019, 58, 5648-5652.	13.8	71
27	Harnessing Intramolecular Rotation To Enhance Twoâ€photon Imaging of AÎ² Plaques through Minimizing Background Fluorescence. Angewandte Chemie, 2019, 131, 5704-5708.	2.0	17
28	Deep proteome profiling of the hippocampus in the 5XFAD mouse model reveals biological process alterations and a novel biomarker of Alzheimerâ€™s disease. Experimental and Molecular Medicine, 2019, 51, 1-17.	7.7	56
29	Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals. Neurobiology of Aging, 2019, 73, 21-29.	3.1	29
30	Nurr1 (NR4A2) regulates Alzheimerâ€™s diseaseâ€related pathogenesis and cognitive function in the 5XFAD mouse model. Aging Cell, 2019, 18, e12866.	6.7	72
31	Amyloid Î²â€induced elevation of Oâ€GlcNAcylated câ€Fos promotes neuronal cell death. Aging Cell, 2019, 18, e12872.	6.7	18
32	The role of cell type-specific mitochondrial dysfunction in the pathogenesis of Alzheimer's disease. BMB Reports, 2019, 52, 679-688.	2.4	19
33	Visualization of Altered Hippocampal Connectivity in an Animal Model of Alzheimerâ€™s Disease. Molecular Neurobiology, 2018, 55, 7886-7899.	4.0	20
34	Regulation of autophagic proteolysis by the N-recognin SQSTM1/p62 of the N-end rule pathway. Autophagy, 2018, 14, 359-361.	9.1	36
35	Thrombospondin-1 protects against AÎ²-induced mitochondrial fragmentation and dysfunction in hippocampal cells. Cell Death Discovery, 2018, 4, 31.	4.7	20
36	Intrahippocampal injection of a lentiviral vector expressing neurogranin enhances cognitive function in 5XFAD mice. Experimental and Molecular Medicine, 2018, 50, e461-e461.	7.7	22

#	Article	IF	Citations
37	SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer's disease. Aging Cell, 2018, 17, e12679.	6.7	142
38	Specific autophagy and ESCRT components participate in the unconventional secretion of CFTR. Autophagy, 2018, 14, 1761-1778.	9.1	46
39	O â€GlcNAcylation regulates endoplasmic reticulum exit sites through Sec31A modification in conventional secretory pathway. FASEB Journal, 2018, 32, 4641-4657.	0.5	18
40	Molecular and functional signatures in a novel Alzheimerâ€™s disease mouse model assessed by quantitative proteomics. Molecular Neurodegeneration, 2018, 13, 2.	10.8	62
41	Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of AÎ²-induced impaired axonal transport. Molecular Neurodegeneration, 2017, 12, 23.	10.8	52
42	TREM2 promotes AÎ² phagocytosis by upregulating C/EBPÎ±-dependent CD36 expression in microglia. Scientific Reports, 2017, 7, 11118.	3.3	79
43	Chemically treated plasma AÎ² is a potential blood-based biomarker for screening cerebral amyloid deposition. Alzheimer's Research and Therapy, 2017, 9, 20.	6.2	50
44	Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 125, 1172-1192.	5.5	26
45	Protein-Induced Pluripotent Stem Cells Ameliorate Cognitive Dysfunction and Reduce AÎ² Deposition in a Mouse Model of Alzheimer's Disease. Stem Cells Translational Medicine, 2017, 6, 293-305.	3.3	58
46	Annexin A1 restores AÎ²_{1â€42}â€induced bloodâ€“brain barrier disruption through the inhibition of RhoAâ€<scp>ROCK</scp> signaling pathway. Aging Cell, 2017, 16, 149-161.	6.7	87
47	[P3â€“236]: CHEMICALLY TREATED PLASMA AÎ² AND ACETYLCHOLINESTERASE LEVELS ARE POTENTIAL BIOMARKERS FOR PREDICTION OF PIBâ€PET POSITIVITY IN THE BRAIN. Alzheimer's and Dementia, 2017, 13, P1028.	0.8	0
48	Low Serum Phosphorus Correlates with Cerebral AÎ² Deposition in Cognitively Impaired Subjects: Results from the KBASE Study. Frontiers in Aging Neuroscience, 2017, 9, 362.	3.4	14
49	Cytosolic Extract of Human Adipose Stem Cells Reverses the Amyloid Beta-Induced Mitochondrial Apoptosis via P53/Foxo3a Pathway. PLoS ONE, 2017, 12, e0168859.	2.5	7
50	Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics. Psychiatry Investigation, 2017, 14, 851.	1.6	75
51	PRAK mediates AÎ²-RAGE driven autophagy pathway. Oncotarget, 2017, 8, 5648-5649.	1.8	1
52	HDAC6 Inhibitors Rescued the Defective Axonal Mitochondrial Movement in Motor Neurons Derived from the Induced Pluripotent Stem Cells of Peripheral Neuropathy Patients with HSPB1 Mutation. Stem Cells International, 2016, 2016, 1-14.	2.5	40
53	Metformin Facilitates Amyloid-Î² Generation by Î²- and Î³-Secretases via Autophagy Activation. Journal of Alzheimer's Disease, 2016, 51, 1197-1208.	2.6	79
54	Inhibition of Cholesterol Biosynthesis Reduces Î³-Secretase Activity and Amyloid-Î² Generation. Journal of Alzheimer's Disease, 2016, 51, 1057-1068.	2.6	22

#	Article	IF	Citations
55	PiB-PET Imaging-Based Serum Proteome Profiles Predict Mild Cognitive Impairment and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 1563-1576.	2.6	24
56	Close Correlation of Monoamine Oxidase Activity with Progress of Alzheimerâ€™s Disease in Mice, Observed by in Vivo Two-Photon Imaging. ACS Central Science, 2016, 2, 967-975.	11.3	94
57	A quadrupolar two-photon fluorescent probe for in vivo imaging of amyloid-Î² plaques. Chemical Science, 2016, 7, 4600-4606.	7.4	49
58	Microglia contributes to plaque growth by cell death due to uptake of amyloid Î² in the brain of Alzheimer's disease mouse model. Glia, 2016, 64, 2274-2290.	4.9	147
59	Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimerâ€™s Disease. ACS Nano, 2016, 10, 2860-2870.	14.6	481
60	Insulin-degrading enzyme secretion from astrocytes is mediated by an autophagy-based unconventional secretory pathway in Alzheimer disease. Autophagy, 2016, 12, 784-800.	9.1	99
61	DMC (2â€²,4â€²-dihydroxy-6â€²-methoxy-3â€²,5â€²-dimethylchalcone) improves glucose tolerance as a potent AMPK activator. Metabolism: Clinical and Experimental, 2016, 65, 533-542.	3.4	17
62	Amyloid Î²-interacting partners in Alzheimer's disease: From accomplices to possible therapeutic targets. Progress in Neurobiology, 2016, 137, 17-38.	5.7	60
63	Global changes of phospholipids identified by MALDI imaging mass spectrometry in a mouse model of Alzheimer's disease. Journal of Lipid Research, 2016, 57, 36-45.	4.2	59
64	AÎ²-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2015, 10, 13.	10.8	108
65	Two-Photon Absorbing Dyes with Minimal Autofluorescence in Tissue Imaging: Application to in Vivo Imaging of Amyloid-Î² Plaques with a Negligible Background Signal. Journal of the American Chemical Society, 2015, 137, 6781-6789.	13.7	181
66	The role of mitochondrial DNA mutation on neurodegenerative diseases. Experimental and Molecular Medicine, 2015, 47, e150-e150.	7.7	114
67	Special issue on neurodegenerative diseases and their therapeutic approaches. Experimental and Molecular Medicine, 2015, 47, e146-e146.	7.7	5
68	Thrombospondin-1 prevents amyloid betaâ€“mediated synaptic pathology in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3214-3227.	3.1	37
69	Mitochondrial ATP synthase activity is impaired by suppressedO-GlcNAcylation in Alzheimer's disease. Human Molecular Genetics, 2015, 24, 6492-6504.	2.9	74
70	LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nature Communications, 2015, 6, 8255.	12.8	79
71	A phosphomimetic mutant TDP-43 (S409/410E) induces Drosha instability and cytotoxicity in Neuro 2A cells. Biochemical and Biophysical Research Communications, 2015, 464, 236-243.	2.1	20
72	Correlation between orphan nuclear receptor Nurr1 expression and amyloid deposition in 5<scp>XFAD</scp> mice, an animal model of Alzheimer's disease. Journal of Neurochemistry, 2015, 132, 254-262.	3.9	34

#	Article	IF	Citations
73	MicroRNA-124 slows down the progression of Huntingtonâ€²s disease by promoting neurogenesis in the striatum. Neural Regeneration Research, 2015, 10, 786.	3.0	46
74	Diverse Molecular Targets for Therapeutic Strategies in Alzheimer's Disease. Journal of Korean Medical Science, 2014, 29, 893.	2.5	21
75	Both Targeted Mass Spectrometry and Flow Sorting Analysis Methods Detected the Decreased Serum Apolipoprotein E Level in Alzheimer's Disease Patients. Molecular and Cellular Proteomics, 2014, 13, 407-419.	3.8	27
76	Migration of neutrophils targeting amyloid plaques in Alzheimer's disease mouse model. Neurobiology of Aging, 2014, 35, 1286-1292.	3.1	146
77	Modulation of mitochondrial function by stem cell-derived cellular components. Biochemical and Biophysical Research Communications, 2014, 448, 403-408.	2.1	9
78	Impaired Hippocampal Neurogenesis and its Enhancement with Ghrelin in 5XFAD Mice. Journal of Alzheimer's Disease, 2014, 41, 233-241.	2.6	94
79	Adenylyl Cyclase-Associated Protein 1 Is a Receptor for Human Resistin and Mediates Inflammatory Actions of Human Monocytes. Cell Metabolism, 2014, 19, 484-497.	16.2	213
80	Intracellular amyloid beta alters the tight junction of retinal pigment epithelium in 5XFAD mice. Neurobiology of Aging, 2014, 35, 2013-2020.	3.1	71
81	Inhibition of Glutaminyl Cyclase Ameliorates Amyloid Pathology in an Animal Model of Alzheimer's Disease via the Modulation of Î³-Secretase Activity. Journal of Alzheimer's Disease, 2014, 43, 797-807.	2.6	12
82	Phosphokinase Antibody Arrays on Dendron-Coated Surface. PLoS ONE, 2014, 9, e96456.	2.5	5
83	Amyloid Beta-Mediated Epigenetic Alteration of Insulin-Like Growth Factor Binding Protein 3 Controls Cell Survival in Alzheimer's Disease. PLoS ONE, 2014, 9, e99047.	2.5	13
84	Mitochondrial dysfunction and calcium deregulation by the RanBP9â€cofilin pathway. FASEB Journal, 2013, 27, 4776-4789.	0.5	27
85	Amelioration of neurodegenerative diseases by cell death-induced cytoplasmic delivery of humanin. Journal of Controlled Release, 2013, 166, 307-315.	9.9	16
86	Synapsin-1 and tau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brain synaptosomes. Experimental and Molecular Medicine, 2013, 45, e29-e29.	7.7	16
87	O-linked Î²-N-acetylglucosaminidase inhibitor attenuates Î²-amyloid plaque and rescues memory impairment. Neurobiology of Aging, 2013, 34, 275-285.	3.1	98
88	A two-photon fluorescent probe for amyloid-Î² plaques in living mice. Chemical Communications, 2013, 49, 1303.	4.1	54
89	Structureâ€"activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. Bioorganic and Medicinal Chemistry, 2013, 21, 3821-3830.	3.0	33
90	Disruption of blood-brain barrier in Alzheimer disease pathogenesis. Tissue Barriers, 2013, 1, e23993.	3.2	72

#	Article	IF	Citations
91	Quantitative Proteomic Analysis of the Hippocampus in the 5XFAD Mouse Model at Early Stages of Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2013, 36, 321-334.	2.6	39
92	Contributions of Microglia to Structural Synaptic Plasticity. Journal of Experimental Neuroscience, 2013, 7, JEN.S11269.	2.3	18
93	Diverse Functions of Î³ -secretase: Releasing Signaling Fragments and Deleterious Molecules. Current Enzyme Inhibition, 2013, 9, 15-27.	0.4	0
94	SORL1 Is Genetically Associated with Late-Onset Alzheimerâ€™s Disease in Japanese, Koreans and Caucasians. PLoS ONE, 2013, 8, e58618.	2.5	149
95	Astrocyte-Originated ATP Protects AÎ²₁₋₄₂-Induced Impairment of Synaptic Plasticity. Journal of Neuroscience, 2012, 32, 3081-3087.	3.6	41
96	RNA-Seq Analysis of Frontal Cortex and Cerebellum from 5XFAD Mice at Early Stage of Disease Pathology. Journal of Alzheimer's Disease, 2012, 29, 793-808.	2.6	43
97	Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy, 2012, 8, 1842-1844.	9.1	82
98	AÂ1-42-RAGE Interaction Disrupts Tight Junctions of the Blood-Brain Barrier Via Ca2+-Calcineurin Signaling. Journal of Neuroscience, 2012, 32, 8845-8854.	3.6	215
99	Impaired Short-Term Plasticity in Mossy Fiber Synapses Caused by Mitochondrial Dysfunction of Dentate Granule Cells Is the Earliest Synaptic Deficit in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 5953-5963.	3.6	71
100	Altered APP Processing in Insulin-Resistant Conditions Is Mediated by Autophagosome Accumulation via the Inhibition of Mammalian Target of Rapamycin Pathway. Diabetes, 2012, 61, 3126-3138.	0.6	69
101	AÎ²-induced Ca2+ influx regulates astrocytic BACE1 expression via calcineurin/NFAT4 signals. Biochemical and Biophysical Research Communications, 2012, 425, 649-655.	2.1	29
102	Mitochondria-Specific Accumulation of Amyloid Î² Induces Mitochondrial Dysfunction Leading to Apoptotic Cell Death. PLoS ONE, 2012, 7, e34929.	2.5	197
103	Intracellular Amyloid-Î² Accumulation in Calcium-Binding Protein-Deficient Neurons Leads to Amyloid-Î² Plaque Formation in Animal Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 615-628.	2.6	53
104	Induction of Neuronal Death by Microglial AGE-Albumin: Implications for Alzheimerâ€™s Disease. PLoS ONE, 2012, 7, e37917.	2.5	66
105	Pyridyl-urea Derivatives as Blockers of AÎ²-induced mPTP Opening for Alzheimer's Disease. Bulletin of the Korean Chemical Society, 2012, 33, 3887-3888.	1.9	3
106	Human Serum Transthyretin Levels Correlate Inversely with Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 25, 77-84.	2.6	76
107	Gami-Chunghyuldan ameliorates memory impairment and neurodegeneration induced by intrahippocampal AÎ²1â€“42 oligomer injection. Neurobiology of Learning and Memory, 2011, 96, 306-314.	1.9	26
108	Ghrelin Ameliorates Cognitive Dysfunction and Neurodegeneration in Intrahippocampal Amyloid-Î²1-42 Oligomer-Injected Mice. Journal of Alzheimer's Disease, 2011, 23, 147-159.	2.6	121

#	Article	IF	Citations
109	Knock-down of protein L-isoaspartyl O-methyltransferase increases Î²-amyloid production by decreasing ADAM10 and ADAM17 levels. Acta Pharmacologica Sinica, 2011, 32, 288-294.	6.1	7
110	RAGE: The Beneficial and Deleterious Effects by Diverse Mechanisms of Actions. Molecules and Cells, 2011, 31, 91-98.	2.6	97
111	A Relationship Between Alzheimer's Disease and Type 2 Diabetes Mellitus Through the Measurement of Serum Amyloid-Î² Autoantibodies. Journal of Alzheimer's Disease, 2010, 19, 1371-1376.	2.6	20
112	UBR2 mediates transcriptional silencing during spermatogenesis via histone ubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1912-1917.	7.1	76
113	O-GlcNAcylation regulates hyperglycemia-induced GPX1 activation. Biochemical and Biophysical Research Communications, 2010, 391, 756-761.	2.1	19
114	FK506 Reduces Amyloid Plaque Burden and Induces MMP-9 in AÎ²PP/PS1 Double Transgenic Mice. Journal of Alzheimer's Disease, 2010, 22, 97-105.	2.6	38
115	Constitutive JAK2/STAT1 activation regulates endogenous BACE1 expression in neurons. Biochemical and Biophysical Research Communications, 2009, 386, 175-180.	2.1	24
116	18F-Labeled benzylideneaniline derivatives as new ligands for Î²-amyloid plaque imaging in Alzheimer's disease. Nuclear Medicine and Biology, 2009, 36, 107-116.	0.6	5
117	Accumulation of Phosphorylated Î²-Catenin Enhances ROS-Induced Cell Death in Presenilin-Deficient Cells. PLoS ONE, 2009, 4, e4172.	2.5	15
118	Aminostyrylbenzofuran derivatives as potent inhibitors for AÎ² fibril formation. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5591-5593.	2.2	55
119	Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT 1) signaling. Aging Cell, 2008, 7, 137-147.	6.7	64
120	Rac1 changes the substrate specificity of Î³-secretase between amyloid precursor protein and Notch1. Biochemical and Biophysical Research Communications, 2008, 372, 913-917.	2.1	25
121	BACE1 (Î²-Secretase) Inhibitory Chromone Glycosides from Aloe vera and Aloe nobilis. Planta Medica, 2008, 74, 540-545.	1.3	37
122	Upregulation of amyloid precursor protein by platelet-derived growth factor in hippocampal precursor cells. NeuroReport, 2007, 18, 1225-1229.	1.2	9
123	Reduced serum level of antibodies against amyloid Î² peptide is associated with aging in Tg2576 mice. Biochemical and Biophysical Research Communications, 2007, 361, 800-804.	2.1	13
124	IFN-Î³-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia, 2007, 55, 253-262.	4.9	100
125	Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for AÎ² fibril formation. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1466-1470.	2.2	33
126	Branched Diacylglycerol-Lactones as Potent Protein Kinase C Ligands and Î±-Secretase Activators. Journal of Medicinal Chemistry, 2006, 49, 2028-2036.	6.4	11

#	Article	IF	Citations
127	Cytosolic amyloid-Î² peptide 42 escaping from degradation induces cell death. Biochemical and Biophysical Research Communications, 2006, 344, 471-477.	2.1	16
128	Furin is an endogenous regulator of Î±-secretase associated APP processing. Biochemical and Biophysical Research Communications, 2006, 349, 654-659.	2.1	65
129	Effect of Ischemic Neuronal Insults on Amyloid Precursor Protein Processing. Neurochemical Research, 2006, 31, 821-827.	3.3	26
130	ERK1/2 is an endogenous negative regulator of the Î³secretase activity. FASEB Journal, 2006, 20, 157-159.	0.5	93
131	Amyloid peptide attenuates the proteasome activity in neuronal cells. Mechanisms of Ageing and Development, 2005, 126, 1292-1299.	4.6	137
132	Transgenic potato expressing AÎ² reduce AÎ² burden in Alzheimer's disease mouse model. FEBS Letters, 2005, 579, 6737-6744.	2.8	29
133	Induction of pro-apoptotic calsenilin/DREAM/KChIP3 in Alzheimer's disease and cultured neurons after amyloid-Î² exposure. Journal of Neurochemistry, 2004, 88, 1570-1570.	3.9	31
134	Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics, 2004, 4, 3359-3368.	2.2	62
135	Role for PKC-Îµ in neuronal death induced by oxidative stress. Biochemical and Biophysical Research Communications, 2004, 320, 789-794.	2.1	35
136	Neuroprotective effect of genistein against beta amyloid-induced neurotoxicity. Neurobiology of Disease, 2004, 16, 21-28.	4.4	118
137	Amyloid beta peptide directly inhibits PKC activation. Molecular and Cellular Neurosciences, 2004, 26, 222-231.	2.2	60
138	Expression of human Î²-amyloid peptide in transgenic potato. Plant Science, 2003, 165, 1445-1451.	3.6	30
139	Contribution of presenilin/Î³-secretase to calsenilin-mediated apoptosis. Biochemical and Biophysical Research Communications, 2003, 305, 62-66.	2.1	27
140	Lovastatin enhances AÎ² production and senile plaque deposition in female Tg2576 mice. Neurobiology of Aging, 2003, 24, 637-643.	3.1	131
141	Neuroprotective Effects of Constituents of the Oriental Crude Drugs, Rhodiola sacra, R. sachalinensis and Tokaku-joki-to, against Beta-amyloid Toxicity, Oxidative Stress and Apoptosis.. Biological and Pharmaceutical Bulletin, 2002, 25, 1101-1104.	1.4	47
142	Amyloid precursor protein processing is separately regulated by protein kinase C and tyrosine kinase in human astrocytes. Neuroscience Letters, 2002, 324, 185-188.	2.1	14
143	Variation in Effective Stimulus Patterns for Induction of Long-Term Potentiation Across Different Layers of Rat Entorhinal Cortex. Journal of Neuroscience, 2002, 22, RC214-RC214.	3.6	45
144	Induction of homosynaptic long-term depression in entorhinal cortex. Brain Research, 2002, 954, 308-310.	2.2	13

#	Article	IF	Citations
145	Blockade of PKCÏµ Activation Attenuates Phorbol Ester-Induced Increase of Î±-Secretase-Derived Secreted Form of Amyloid Precursor Protein. Biochemical and Biophysical Research Communications, 2001, 280, 782-787.	2.1	54
146	Zinc Enhances Synthesis of Presenilin 1 in Mouse Primary Cortical Culture. Biochemical and Biophysical Research Communications, 2001, 285, 680-688.	2.1	23
147	Haloperidol and clozapine increase neural activity in the rat prefrontal cortex. Neuroscience Letters, 2001, 298, 217-221.	2.1	11
148	Neuroprotective effects of estrogen against beta-amyloid toxicity are mediated by estrogen receptors in cultured neuronal cells. Neuroscience Letters, 2001, 302, 58-62.	2.1	73
149	Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in mice. Journal of Neuroscience Research, 2001, 63, 509-515.	2.9	127
150	Cholinergic modulation of synaptic physiology in deep layer entorhinal cortex of the rat. Journal of Neuroscience Research, 2001, 66, 117-121.	2.9	25
151	Negative Regulation of the Sapk/Jnk Signaling Pathway by Presenilin 1. Journal of Cell Biology, 2001, 153, 457-464.	5.2	28
152	Structureâ€“activity relationship study of asiatic acid derivatives against beta amyloid (AÎ²)-induced neurotoxicity. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 119-121.	2.2	64
153	Relationship among Discharges of Neighboring Neurons in the Rat Prefrontal Cortex During Spatial Working Memory Tasks. Journal of Neuroscience, 2000, 20, 6166-6172.	3.6	28
154	Is Understanding the Biological Function of APP Important in Understanding Alzheimer's Disease?*. Journal of Alzheimer's Disease, 1999, 1, 287-295.	2.6	5
155	Histochemically Reactive Zinc in Plaques of the Swedish Mutant Î²-Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 1999, 19, RC10-RC10.	3.6	116
156	Presenilin 1 mediates protein kinase C dependent Î±-secretase derived amyloid precursor protein secretion and mitogen-activated protein kinase activation in presenilin 1 transfected human embryonic kidney 293 cell. Neuroscience Letters, 1999, 269, 99-102.	2.1	8
157	Amyloid precursor protein activates phosphotyrosine signaling pathway. Neuroscience Letters, 1997, 235, 1-4.	2.1	11
158	Estrogen blocks neurotoxic effects of Î²-amyloid (1â€“42) and induces neurite extension on B103 cells. Neuroscience Letters, 1997, 235, 101-104.	2.1	64
159	Acetylcholine receptor clustering associates with proteoglycan biosynthesis in C2 variant and heterkaryon muscle cells. Journal of Neurobiology, 1996, 31, 210-218.	3.6	5
160	Acetylcholine receptor clustering in C2 muscle cells requires chondroitin sulfate. Journal of Neurobiology, 1995, 28, 482-492.	3.6	23